神经源性高血压,一种复杂的多因素心血管疾病,已知受到各种遗传的影响,环境,和生活方式因素。近年来,人们越来越关注肠道微生物组在高血压发病机制中的作用.肠道菌群和中枢神经系统之间的双向通信,被称为微生物群-肠-脑轴,已经成为肠道微生物群对神经炎症产生影响的关键机制,免疫反应,和血压调节。最近的研究表明,微生物组如何对各种生理功能产生重大影响,比如心血管健康。肠道交感神经活动的增加可能会导致微生物菌群失调,肠道通透性增加,通过改变许多产生短链脂肪酸(SCFA)的肠道细菌和血浆中脂多糖(LPS)的浓度来增加炎症反应。总的来说,这些微生物代谢和结构化合物刺激交感神经刺激,这可能是高血压发作的重要阶段。结果是外周和中枢炎症反应的激增。此外,最近的研究表明,免疫系统和肠道微生物群之间的联系可能在高血压中起重要作用。肠道微生物组的治疗意义,包括益生菌的使用,益生元,饮食调整,和粪便微生物移植在神经源性高血压中也被发现。大量研究表明,益生菌补充剂可能有助于减少与肠道微生物群生态失调相关的慢性炎症和高血压。总的来说,这篇综述揭示了肠道微生物组和神经源性高血压之间复杂的相互作用,为研究人员和临床医生提供有价值的见解。随着我们对微生物组在高血压中的作用的认识的扩大,新的治疗策略和诊断性生物标志物可能为更有效地治疗和预防这种普遍存在的心血管疾病铺平道路.探索高血压中微生物组的潜力为未来的研究提供了令人兴奋的途径,并为精准医学和改善患者护理提供了机会。
Neurogenic hypertension, a complex and multifactorial cardiovascular disorder, is known to be influenced by various genetic, environmental, and lifestyle factors. In recent years, there has been growing interest in the role of the gut microbiome in hypertension pathogenesis. The bidirectional communication between the gut microbiota and the central nervous system, known as the microbiota-gut-brain axis, has emerged as a crucial mechanism through which the gut microbiota exerts its influence on neuroinflammation, immune responses, and blood pressure regulation. Recent studies have shown how the microbiome has a substantial impact on a variety of physiological functions, such as cardiovascular health. The increased sympathetic activity to the gut may cause microbial dysbiosis, increased permeability of the gut, and increased inflammatory reactions by altering a number of intestinal bacteria producing short-chain fatty acids (SCFAs) and the concentrations of lipopolysaccharide (LPS) in the plasma. Collectively, these microbial metabolic and structural compounds stimulate sympathetic stimulation, which may be an important stage in the onset of hypertension. The result is an upsurge in peripheral and central inflammatory response. In addition, it has recently been shown that a link between the immune system and the gut microbiota might play a significant role in hypertension. The therapeutic implications of the gut microbiome including probiotic usage, prebiotics, dietary modifications, and fecal microbiota transplantation in neurogenic hypertension have also been found. A large body of research suggests that probiotic supplementation might help reduce chronic inflammation and hypertension that have an association with dysbiosis in the gut microbiota. Overall, this
review sheds light on the intricate interplay between the gut microbiome and neurogenic hypertension, providing valuable insights for both researchers and clinicians. As our knowledge of the microbiome\'s role in hypertension expands, novel therapeutic strategies and diagnostic biomarkers may pave the way for more effective management and prevention of this prevalent cardiovascular disorder. Exploring the potential of the microbiome in hypertension offers an exciting avenue for future research and offers opportunities for precision medicine and improved patient care.